(Q35692736)

9 August 2017

1 reference

title

Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections (English)

1 reference

9 August 2017

1 reference

1 reference

Nuermberger E

1

1 reference

PubMed ID

15024625

9 August 2017

Grosset J

series ordinal

2

1 reference

9 August 2017

13 March 2004

1 reference

European Journal of Clinical Microbiology & Infectious Diseases

9 August 2017

1 reference

9 August 2017

23

1 reference

9 August 2017

4

1 reference

9 August 2017

243-255

1 reference

https://scigraph.springernature.com/pub.10.1007/s10096-004-1109-5

9 August 2017

0 references

cites work

Does In Vitro Susceptibility to Rifabutin and Ethambutol Predict the Response to Treatment ofMycobacterium aviumComplex Bacteremia with Rifabutin, Ethambutol, and Clarithromycin?

1 reference

12 December 2020

Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis

1 reference

12 December 2020

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis

1 reference

12 December 2020

Mycobacterium avium strains resistant to clarithromycin and azithromycin

1 reference

12 December 2020

Tuberculosis chemotherapy: still a double-edged sword

1 reference

12 December 2020

In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

1 reference

12 December 2020

Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.

1 reference

12 December 2020

The eradication of tuberculosis: Theoretical problems and practical solutions

1 reference

12 December 2020

Treatment of multidrug-resistant tuberculosis

1 reference

12 December 2020

The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment

1 reference

12 December 2020

A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment

1 reference

12 December 2020

Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species

1 reference

12 December 2020

Treatment of pulmonary infections caused by mycobacteria of the Mycobacterium avium-intracellulare complex

1 reference

12 December 2020

A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome

1 reference

12 December 2020

Therapeutic drug monitoring in the treatment of tuberculosis

1 reference

12 December 2020

Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models

1 reference

12 December 2020

Mycobacterium tuberculosis in the Extracellular Compartment: an Underestimated Adversary

1 reference

12 December 2020

Selection of clarithromycin-resistant Mycobacterium avium complex during combined therapy using the beige mouse model

1 reference

12 December 2020

A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen

1 reference

12 December 2020

Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America.

1 reference

12 December 2020

Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France.

1 reference

12 December 2020

No evidence for effects of family environment on asthma. A retrospective study of Norwegian twins.

1 reference

12 December 2020

Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine

1 reference

12 December 2020

Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide

1 reference

12 December 2020

Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus

1 reference

12 December 2020

Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis.

1 reference

12 December 2020

Treating disseminated Mycobacterium avium-intracellulare infection

1 reference

12 December 2020

Combinations of rifampin or rifabutine plus ethambutol against Mycobacterium avium complex. Bactericidal synergistic, and bacteriostatic additive or synergistic effects

1 reference

12 December 2020

Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community

1 reference

12 December 2020

Postantibiotic effects of antituberculosis agents alone and in combination

1 reference

12 December 2020

Clinical Pharmacokinetics of Isoniazid

1 reference

12 December 2020

Basic Mechanisms of Chemotherapy

1 reference

12 December 2020

Role of individual drugs in the chemotherapy of tuberculosis

1 reference

12 December 2020

THE PREVENTION AND TREATMENT OF ISONIAZID TOXICITY IN THE THERAPY OF PULMONARY TUBERCULOSIS. 2. AN ASSESSMENT OF THE PROPHYLACTIC EFFECT OF PYRIDOXINE IN LOW DOSAGE

1 reference

12 December 2020

Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS.

1 reference

12 December 2020

Pulmonary disease due to Mycobacterium intracellulare.

1 reference

12 December 2020

Killing and regrowth of bacteria in vitro: a review.

1 reference

12 December 2020

Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis

1 reference

12 December 2020

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

1 reference

12 December 2020

Decreased acetylation of isoniazid in chronic renal failure

1 reference

12 December 2020

Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens

1 reference

12 December 2020

Application of fluoroquinolone pharmacodynamics

1 reference

12 December 2020

Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.

1 reference

12 December 2020

Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis

1 reference

12 December 2020

Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone

1 reference

12 December 2020

The beige mutation in the mouse. I. A stem cell predetermined impairment in natural killer cell function

1 reference

12 December 2020

Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice

1 reference

12 December 2020

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

12 December 2020

Bacteriologic basis of short-course chemotherapy for tuberculosis.

1 reference

12 December 2020

Activity of azithromycin against Mycobacterium avium infection in beige mice

1 reference

12 December 2020

The Garrod Lecture. Understanding the chemotherapy of tuberculosis--current problems

1 reference

12 December 2020

Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium

1 reference

12 December 2020

Metabolism and pharmacokinetics of the antibiotic rifampin

1 reference

12 December 2020

In vitro and in vivo studies to assess the suitability of antituberculous drugs for use in intermittent chemotherapy regimens.

1 reference

12 December 2020

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

1 reference

12 December 2020

Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model

1 reference

12 December 2020

The early bactericidal activity of drugs in patients with pulmonary tuberculosis

1 reference

12 December 2020

Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population

1 reference

12 December 2020

Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects

1 reference

12 December 2020

Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects

1 reference

12 December 2020

A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex

1 reference

12 December 2020

The curious characteristics of pyrazinamide: a review

1 reference

12 December 2020

Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations

1 reference

12 December 2020

Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. 3. Serum concentrations of isoniazid produced by three regimens of isoniazid alone and one of isoniazid plus PAS.

1 reference

12 December 2020

Low access to a highly effective therapy: a challenge for international tuberculosis control.

1 reference

12 December 2020

In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis

1 reference

12 December 2020

The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis

1 reference

12 December 2020

The effect of pulsed exposures to rifampin on the uptake of uridine- 14 C by Mycobacterium tuberculosis

1 reference

12 December 2020

Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group

1 reference

12 December 2020

Effect of combined therapy with ansamycin, clofazimine, ethambutol, and isoniazid for Mycobacterium avium infection in patients with AIDS.

1 reference

12 December 2020

What is the 'right' dose of rifampin?

1 reference

12 December 2020

The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis

1 reference

12 December 2020

Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex

1 reference

12 December 2020

Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis

1 reference

12 December 2020

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

1 reference

12 December 2020

Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers

1 reference

12 December 2020

Suitability of rifampicin for intermittent administration in the treatment of tuberculosis

1 reference

12 December 2020

Is pyrazinamide bactericidal against Mycobacterium tuberculosis?

1 reference

12 December 2020

A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study G

1 reference

12 December 2020

The value of in vitro drug activity and pharmacokinetics in predicting the effectiveness of antimycobacterial therapy: a critical review

1 reference

12 December 2020

Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials

1 reference

12 December 2020

Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group

1 reference

12 December 2020

Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial

1 reference

12 December 2020

Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS

1 reference

12 December 2020

In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis

1 reference

12 December 2020

Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients

1 reference

12 December 2020

U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis

1 reference

12 December 2020

A concurrent comparison of isoniazid plus PAS with three regimens of isoniazid alone in the domiciliary treatment of pulmonary tuberculosis in South India

1 reference

12 December 2020

Activity of clarithromycin against Mycobacterium avium complex infection in beige mice

1 reference

12 December 2020

Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.

1 reference

12 December 2020

Medical management of pulmonary disease caused by Mycobacterium avium complex

1 reference

12 December 2020

A four-drug regimen for initial treatment of cavitary disease caused by Mycobacterium avium complex

1 reference

12 December 2020

High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection

1 reference

12 December 2020

10.1007/S10096-004-1109-5

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

15024625